# Epidarex Capital

> Epidarex Capital is a VC fund backing Biotechnology and Health Care. See 50 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Bethesda, United States
- Total investments: 50
- Last investment: Aug 2026
- Lead investor: 46%
- Last fund: Dec 2019
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/epidarex-capital
- Website: http://epidarex.com

Epidarex Capital is a VC fund in Bethesda focused on Biotechnology and Health Care. Epidarex Capital invests in early-stage, high growth life science and health technology companies in under-ventured markets. Its international team is led by Sinclair Dunlop, Kyp Sirinakis and Liz Roper. With offices in the United States and United Kingdom Epidarex Capital’s investors represent a cross-section of leading universities, internationalcorporations, development agencies and financial institutions. Epidarex was created to meet the need for more sector-specific financial backing for young companies, including spin-outs from leading research universities.

## Contacts

5 contacts available for Epidarex Capital. Shizune tracks 5 team members at Epidarex Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/epidarex-capital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $531k–$8.5M |
| Series A | $2.6M–$38M |
| Series B | $2.4M–$48M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 21 | 42% |
| Health Care | 14 | 28% |
| Therapeutics | 13 | 26% |
| Medical | 7 | 14% |
| Life Science | 5 | 10% |

22 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 21 | 42% |
| Series B | 7 | 14% |
| Seed | 6 | 12% |
| Funding Round | 2 | 4% |
| Venture - Series Unknown | 2 | 4% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 18 | 36% |
| United States | 7 | 14% |
| Germany | 2 | 4% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Elizabeth Roper | Partner | 6 | https://shizune.co/investors/profile/elizabeth-roper |
| Peter Finan | Partner | 6 | https://shizune.co/investors/profile/peter-finan |
| Terri Burke | Venture Partner | 1 | https://shizune.co/investors/profile/terri-burke |
| Kyparissia Sirinakis | Founder & Managing Partner | 1 | https://shizune.co/investors/profile/kyparissia-sirinakis |
| Sinclair Dunlop | Managing Partner | 2 | https://shizune.co/investors/profile/sinclair-dunlop |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Mironid | Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network. | $46M | Series B | Aug 05, 2026 |  |
| RapidPulse | RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinoutof Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry | $48M | Series B | Jul 16, 2026 |  |
| Leucid Bio | Leucid Bio is a pioneering biotech company developing cell therapies for refractory cancers, especially solid tumors. Leucid was founded to translate 20 years of King's College London (King's) research in the CAR-T field and is led by a highly experienced management team with both scientific and commercial expertise. As part ofLeucid's ongoing relationship with King's, it benefits from exclusive access to and resources from the deep scientific, clinical, and manufacturing expertise of Dr. Maher and his academic team of immuno-oncology experts. | $8.9M | Series A | Feb 01, 2025 |  |
| Harness Therapeutics | Transine Therapeutics is a private biotechnology company focused on the development of a novel class of therapeutic RNAs that can upregulate protein expression with an unprecedented level of control and specificity: the SINEUPs®. The company's pioneering technology is expected to offer an entirely unique mechanism of action for currentlyhard-to-treat diseases by massively extending the druggable proteome and allowing it to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. |  |  | Jan 27, 2025 |  |
| Epsilogen | IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor. | $16.3M | Series B | Sep 09, 2024 |  |
| Ryme Medical | Ryme Medical is a company that develops therapies aimed at treating individuals suffering from chronic bronchitis and emphysema. The organization focuses on addressing chronic obstructive pulmonary disease by targeting the sympathetic nervous system, mitigating its effects, and alleviating the distress of those who struggle to breathe. Thisapproach allows patients to receive improved treatment and breathe with greater ease. |  | Series A | Aug 21, 2024 |  |
| Theolytics | Theolytics is a clinical stage biotechnology company harnessing viruses to combat disease. A step-change in the adenoviral therapy field, our phenotypic screening Platform enables the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population. In addition toadvancing an internal Pipeline of programs spanning both solid and liquid tumours, we are establishing select strategic partnerships to expand and accelerate pipeline development. | $23.7M | Venture - Series Unknown | Apr 17, 2024 |  |
| Curve Therapeutics | Curve has developed an innovative screening platform that is transforming the discovery of first-in-class therapeutics. The platform allows functional screening of diverse, genetically encoded Microcycle™ libraries against a broad range of disease-associated targets that are present in their native conformation inside a mammalian cell. Curve isdeploying this platform to build a pipeline of novel cancer drugs. | $51.4M | Series A | Feb 27, 2024 |  |
| Enterprise Therapeutics | Enterprise Therapeutics is a drug discovery company dedicated to the researchand development of novel therapies for the treatment of respiratory diseases.In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlyingmechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life. | $33.1M | Series B | Jan 29, 2024 |  |
| Mironid | Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network. | $38.3M | Series A | Sep 13, 2023 |  |

10 of 50 investments shown.

## Co-investors
- [Scottish Investment Bank](https://shizune.co/investors/profile/scottish-investment-bank) — VC Fund, 6 deals together
- [Novartis Venture Fund](https://shizune.co/investors/profile/novartis-venture-fund) — VC Fund, 5 deals together
- [Sante Ventures](https://shizune.co/investors/profile/sante-ventures) — VC Fund, 5 deals together
- [Sofinnova Partners](https://shizune.co/investors/profile/sofinnova-partners) — VC Fund, 5 deals together
- [IP Group](https://shizune.co/investors/profile/ip-group-plc) — VC Fund, 4 deals together
- [Scottish Enterprise](https://shizune.co/investors/profile/scottish-enterprise) — VC Fund, 4 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [Fuel Ventures](https://shizune.co/investors/profile/fuel-ventures-fund) — VC Fund
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in Europe](https://shizune.co/investors/biotechnology-investors-europe)
- [Biotechnology VC Funds in Europe](https://shizune.co/investors/biotechnology-vc-funds-europe)
- [Biotech Investors in Europe](https://shizune.co/investors/biotech-investors-europe)
- [Biotech VC Funds in Europe](https://shizune.co/investors/biotech-vc-funds-europe)
- [Health Care Investors in United Kingdom](https://shizune.co/investors/health-care-investors-united-kingdom)
- [Health Care VC Funds in United Kingdom](https://shizune.co/investors/health-care-vc-funds-united-kingdom)

## FAQ

### What does Epidarex Capital invest in?

Epidarex Capital invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 50 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Epidarex Capital's check size?

Epidarex Capital typically joins rounds of $531k–$8.5M at Seed, $2.6M–$38M at Series A and $2.4M–$48M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Epidarex Capital participates in.

### How do I contact Epidarex Capital?

Public channels for Epidarex Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Epidarex Capital?

The team at Epidarex Capital includes Elizabeth Roper (Partner), Peter Finan (Partner) and Terri Burke (Venture Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co